Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) saw a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 2 shares, a decrease of 92.0% from the April 15th total of 25 shares. Based on an average daily volume of 510 shares, the days-to-cover ratio is currently 0.0 days.
Oculis Stock Performance
OCSAW stock traded up $1.30 during trading on Wednesday, hitting $22.30. 200 shares of the stock traded hands, compared to its average volume of 3,581. Oculis has a 1 year low of $4.85 and a 1 year high of $22.64. The firm’s 50 day moving average is $16.12 and its two-hundred day moving average is $13.20.
About Oculis
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Featured Articles
- Five stocks we like better than Oculis
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
